Drug stocks were mixed in early action Thursday with shares of Myriad Genetics Inc. climbing on news that it has signed a deal with Swedish drug conglomerate H. Lundbeck A/S for the European commercialization of Myriad's Alzheimer's drug candidate Flurizan.
50356
Drug stocks mixed;
148890
European stocks end mixed
170531
Stocks end mixed...
72368
Bears mauling this drug maker's shares
112289
Drug stocks retract;
119643
Stock prices close mixed
62193
Jazz Pharmaceuticals plc enters oversold territory
60653
European markets trade mixed
112374
AdnaGen enters into agreement to license antibodies to KellBenx
65487
Amgen selling Japanese rights to some drugs
143807
European index futures point to mixed start
140472
Indexes slip into mixed territory
87274
European shares rise in early trade
113962
Drug stocks advance;
138125
Platinex issues common shares
143750
Asian stocks mixed
91142
Pfizer leans toward spinoff